Idorsia urgently calls for review of the conditions of a convertible loan

The Rhine laboratory Idorsia, in difficulties with its cash flow, plans to urgently invite the holders of the shares of a convertible loan of 200 million francs maturing on January 17. The maneuver is part of negotiations that are less rapid than expected for the monetization of rights to the anti-hypertension drug aprocitentan.

Idorsia underlines in this regard that the talks with a still unidentified partner are likely to be unsuccessful, if necessary, with…